NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market
NLS Pharmaceutics (Nasdaq: NLSP) announced a private placement offering of up to 322,580 common shares at $3.10 per share, representing a 15% premium to market price, for total gross proceeds of up to $1.0 million. The offering will be executed in two tranches: an initial closing of $500,000 expected by January 10, 2025, and a potential subsequent closing of another $500,000 within 15 days following specific conditions, including shareholder approval and maintaining share price above $3.10 for ten consecutive trading days. The company plans to use proceeds for general corporate purposes.
NLS Pharmaceutics (Nasdaq: NLSP) ha annunciato un'offerta di collocamento privato di fino a 322.580 azioni ordinarie a $3,10 per azione, che rappresenta un premio del 15% rispetto al prezzo di mercato, per un'incasso lordo totale di fino a $1,0 milione. L'offerta sarà eseguita in due tranche: una chiusura iniziale di $500.000 prevista entro il 10 gennaio 2025, e una potenziale successiva chiusura di ulteriori $500.000 entro 15 giorni in base a specifiche condizioni, tra cui l'approvazione degli azionisti e il mantenimento del prezzo delle azioni sopra $3,10 per dieci giorni di negoziazione consecutivi. L'azienda prevede di utilizzare i proventi per scopi aziendali generali.
NLS Pharmaceutics (Nasdaq: NLSP) anunció una oferta privada de colocación de hasta 322,580 acciones comunes a $3.10 por acción, lo que representa una prima del 15% sobre el precio de mercado, para unos ingresos brutos totales de hasta $1.0 millón. La oferta se llevará a cabo en dos tramos: un cierre inicial de $500,000 que se espera para el 10 de enero de 2025, y un posible cierre posterior de otros $500,000 dentro de los 15 días siguientes a ciertas condiciones específicas, incluidas la aprobación de los accionistas y el mantenimiento del precio de las acciones por encima de $3.10 durante diez días de negociación consecutivos. La empresa planea utilizar los ingresos para fines corporativos generales.
NLS Pharmaceutics (Nasdaq: NLSP)는 주당 $3.10에 최대 322,580주 보통주에 대한 사모 배정을 발표했으며, 이는 시장 가격보다 15% 높은 가격입니다. 총 매출은 최대 $1.0 백만에 이릅니다. 이번 제안은 두 개의 트랜치로 실행될 예정입니다: 초기 마감으로 $500,000이 2025년 1월 10일로 예상되며, 이후 15일 이내에 특정 조건(주주 승인 및 10일 연속 거래일 동안 주가가 $3.10 이상 유지)을 충족할 경우 추가로 $500,000을 마감할 수 있습니다. 회사는 이 수익금을 일반적인 회사 운영에 사용할 계획입니다.
NLS Pharmaceutics (Nasdaq: NLSP) a annoncé une offre de placement privé de jusqu'à 322,580 actions ordinaires au prix de $3,10 par action, représentant une prime de 15 % par rapport au prix du marché, pour des recettes brutes totales allant jusqu'à $1,0 million. L'offre sera exécutée en deux tranches : une clôture initiale de 500 000 $ est prévue d'ici le 10 janvier 2025, et une éventuelle clôture subséquente d'un autre 500 000 $ dans un délai de 15 jours suivant certaines conditions spécifiques, y compris l'approbation des actionnaires et le maintien du prix de l'action au-dessus de 3,10 $ pendant dix jours de négociation consécutifs. L'entreprise prévoit d'utiliser les recettes à des fins générales d'entreprise.
NLS Pharmaceutics (Nasdaq: NLSP) hat eine Privatplatzierung von bis zu 322.580 Stammaktien zu $3,10 pro Aktie angekündigt, was einem Aufpreis von 15% im Vergleich zum Marktpreis entspricht, mit einem gesamten Bruttoerlös von bis zu $1,0 Millionen. Das Angebot wird in zwei Tranchen ausgeführt: Ein initialer Abschluss von $500.000 wird bis zum 10. Januar 2025 erwartet, sowie eine potenzielle nachfolgende Abschluss von weiteren $500.000 binnen 15 Tagen unter bestimmten Bedingungen, darunter die Genehmigung der Aktionäre und die Beibehaltung des Aktienkurses über $3,10 für zehn aufeinanderfolgende Handelstage. Das Unternehmen plant, die Einnahmen für allgemeine Unternehmenszwecke zu verwenden.
- Private placement priced at 15% premium to market value
- Secured potential funding of up to $1 million
- Offering subject to shareholder approval
- Second tranche of $500,000 contingent on maintaining stock price above $3.10
- Potential dilution for existing shareholders
Insights
This private placement deal represents a unique financing structure for NLS Pharmaceutics, with several noteworthy aspects. The
The
The conditional nature of the second tranche creates uncertainty around the full funding amount, making this a somewhat precarious financing solution. The requirement for sustained trading above the offering price could prove challenging in current market conditions.
The Company intends to use the net proceeds from the offering for general corporate purposes.
The securities described above were offered pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be offered or sold in
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About NLS Pharmaceutics Ltd.
NLS is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in
Safe Harbor Statement
This press release contains expressed or implied forward-looking statements pursuant to
Contact:
Investor Relations Contact
InvestorRelations@nls-pharma.com
www.nlspharma.com
View original content:https://www.prnewswire.com/news-releases/nls-pharmaceutics-ltd-announces-pricing-of-private-placement-of-up-to-1-million-at-a-15-premium-to-the-market-302322843.html
SOURCE NLS Pharmaceutics Ltd.
FAQ
What is the price per share for NLS Pharmaceutics (NLSP) private placement announced on December 4, 2024?
How much is NLS Pharmaceutics (NLSP) raising in their December 2024 private placement?
When is the expected closing date for NLSP's initial private placement tranche?